Make sure your care provider is aware of your medical history and any other drugs you may be taking
Imaging 14 , e012174 (2021)
Medications like Wegovy and other GLP-1 drugs are now being prescribed to some teenagers struggling with obesity, raising questions among parents, doctors, and researchers about the benefits, risks, and long-term impact on children
These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk
Leah Joseph, MD at JosephCareRX, is here to assist patients in understanding and managing insurance prior authorization for GLP-1s, ensuring smoother access to the medication
